Journal of Modern OncologyJournal of Modern Oncology1815-14341815-1442LLC Obyedinennaya Redaktsiya7794010.26442/18151434.2021.2.200957Review ArticleAcalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidencePetrenkoAndrei A.<p>Graduate Student</p>petrenkoandrei13@gmail.comhttps://orcid.org/0000-0001-8461-5421KislovaMaria I.<p>Student</p>petrenkoandrei13@gmail.comhttps://orcid.org/0000-0002-8794-0120DmitrievaElena A.<p>hematologist</p>petrenkoandrei13@gmail.comhttps://orcid.org/0000-0002-3866-4510NikitinEugene A.<p>D. Sci. (Med.), Prof.</p>petrenkoandrei13@gmail.comhttps://orcid.org/0000-0002-2490-1263Botkin City Clinical HospitalRussian Medical Academy of Continuous Professional EducationSechenov First Moscow State Medical University (Sechenov University)National Research Center for Hematology160820212323323381308202113082021Copyright © 2021, Consilium Medicum2021<p>Chronic lymphocytic leukemia (CLL) treatment landscape has changed dramatically with the recently developed drugs targeting the B-cell receptor (BCR) signalling pathway. Acalabrutinib, a second generation Bruton tyrosine kinase inhibitor, was approved in 2020 in Russia for the treatment of patients with CLL. Acalabrutinib was developed as a more selective Bruton tyrosine kinase inhibitor then ibrutinib. This drug is aimed at reducing the adverse events that limit the use of ibrutinib, such as atrial fibrillation and bleeding. Phase I/II multicenter studies have demonstrated the efficacy and safety of acalabrutinib monotherapy in untreated CLL patients and in patients with relapsed/refractory CLL and ibrutinib intolerance. Phase III trials, ASCEND and ELEVATE-TN, compared acalabrutinib monotherapy and a combination of acalabrutinib and obinutuzumab versus standard therapies and demonstrated improved efficacy and tolerability of acalabrutinib. A phase III trial comparing acalabrutinib and ibrutinib monotherapy (ELEVATE-RR) is ongoing. The results of this study along with real-life clinical data could determine the place of acalabrutinib in CLL treatment.</p>acalabrutinibibrutinibBruton tyrosine kinase inhibitorstarget agentschronic lymphocytic leukemiaatrial fibrillationbleedingакалабрутинибибрутинибингибиторы тирозинкиназы Брутонатаргетные препаратыхронический лимфолейкозфибрилляция предсердийкровотечение[Brown JR, Hallek MJ, Pagel JM. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination? Am Soc Clin Oncol Educ Book. 2016;35:e387-98.DOI:10.1200/EDBK_159018][Hallek M. Chemoimmunotherapy – towards real progress in the treatment of chronic lymphocytic leukemia. Nat Clin Pract Oncol. 2005;2(7):338-9. DOI:10.1038/ncponc0202. PMID: 16075789][Burger JA, O’Brien S. Evolution of CLL treatment – from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15(8):510-27. DOI:10.1038/s41571-018-0037-8][Jain N, Thompson P, Ferrajoli A, et al. Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. Am Soc Clin Oncol Educ Book. 2018;38:580-91. DOI:10.1200/EDBK_200691][Smith CI. From identification of the BTK kinase to effective management of leukemia. Oncogene. 2017;36(15):2045-53. DOI:10.1038/onc.2016.343][Burger JA, Tedeschi A, Barr PM, et al; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373(25):2425-37. DOI:10.1056/NEJMoa1509388][Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-506. DOI:10.1182/blood-2014-10-606038][Barr PM, Robak T, Owen C, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103(9):1502-10. DOI:10.3324/haematol.2018.192328][Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810-7. DOI:10.1182/blood-2013-09-527853][Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796-805. DOI:10.3324/haematol.2017.171041][Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138-40. DOI:10.1182/blood-2016-05-712828][Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015;1(1):80-7. DOI:10.1001/jamaoncol.2014.218][Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9(1):80. DOI:10.1186/s13045-016-0313-y][Ghia P, Dlugosz-Danecka M, Scarfò L, Jurczak W. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2021;62(5):1066-76. DOI:10.1080/10428194.2020.1864352][Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286-94. DOI:10.1056/NEJMoa1400029][Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014;370(24):2352-4. DOI:10.1056/NEJMc1402716. Erratum in: N Engl J Med. 2014;370(26):2547. Perez, Alijandro R [corrected to Perez, Alexendar R].][Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21. DOI:10.1186/s13045-016-0250-9][Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. J Pharmacol Exp Ther. 2017;363(2):240-52. DOI:10.1124/jpet.117.242909][Isaac K, Mato AR. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data. Cancer Manag Res. 2020;12:2079-85. DOI:10.2147/CMAR.S219570][Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020;38(25):2849-61. DOI:10.1200/JCO.19.03355][Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278-91. DOI:10.1016/S0140-6736(20)30262-2. Erratum in: Lancet. 2020;395(10238):1694.][Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 2012;31(2):119-32. DOI:10.3109/08830185.2012.664797. Erratum in: Int Rev Immunol. 2012;31(5):428.][Hendriks RW, Bredius RG, Pike-Overzet K, Staal FJ. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opin Ther Targets. 2011;15(8):1003-21. DOI:10.1517/14728222.2011.585971][Alinari L, Quinion C, Blum KA. Bruton’s tyrosine kinase inhibitors in B-cell non-Hodgkin’s lymphomas. Clin Pharmacol Ther. 2015;97(5):469-77. DOI:10.1002/cpt.65][Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003;21:841-94. DOI:10.1146/annurev.immunol.21.120601.141018][Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5(4):251-62. DOI:10.1038/nrc1589. PMID: 15803153][Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(4):323-32. DOI:10.1056/NEJMoa1509981][Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-80. DOI:10.1073/pnas.1004594107][Patel V, Balakrishnan K, Bibikova E, et al. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017;23(14):3734-43. DOI:10.1158/1078-0432.CCR-16-1446][Series J, Garcia C, Levade M, et al. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Haematologica. 2019;104(11):2292-9. DOI:10.3324/haematol.2018.207183][AstraZeneca Pharmaceuticals LP. Calquence approved in the US for adult patients with chronic lymphocytic leukaemia [press release]; [cited 2019 December 17]. Available at: https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html. Accessed: 04.03.2021.][Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135(15):1204-13. Available at: https://pubmed.ncbi.nlm.nih.gov/ ?term=Byrd+JC%2C+Wierda+WG%2C+Schuh+A%2C+et+al.+Acalabrutinib+monotherapy+in+patients+with+relapsed%2Frefractory+chronic+lymphocytic+leukemia%3A+updated+phase+2+results.+Blood.+2020%3B135%2815%29%3A1204-13&filter=simsearch1.fha&filter=simsearch2.ffrft&filter=simsearch3.fft&filter= pubt.clinicaltrial&filter=pubt.meta-analysis&filter=pubt.systematicreview. Accessed: 04.03.2021.][Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3(9):1553-62. DOI:10.1182/bloodadvances.2018030007][Byrd JC, WoyachJA, Furman RR, et al. Acalabrutinib in treatment-naive chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability. J Clin Oncol. 2020;38(15 suppl.):8024. DOI:10.1200/JCO.2020.38.15_suppl.8024][Rogers KA, Thompson PA, Allan JN, et al. Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J Clin Oncol. 2019;37(15 suppl.):7530. DOI:10.1200/JCO.2019.37.15_suppl.7530][Woyach JA, Blachly JS, Rogers KA, et al. Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia. Cancer Discov. 2020;10(3):394-405. DOI:10.1158/2159-8290.CD-19-1130][Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018;379(26):2517-28. DOI:10.1056/NEJMoa1812836][Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43-56. DOI:10.1016/S1470-2045(18)30788-5][Byrd, J et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. Abstract #7500 Oral Abstract Session Hematologic Malignancies 7 June 2021.][Brown JR, Eichhorst BF, Ghia P, et al. A phase 3 trial comparing the efficacy and safety of acalabrutinib in combination with venetoclax with or without obinutuzumab, compared with investigator’s choice of chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL) without Del(17p) or TP53 mutation. Blood. 2019;134(Suppl. 1):4318.][Lampson B, Tyekucheva S, Crombie J, et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL). Blood. 2019;134(Suppl. 1):32.][Byrd JC, Owen R, O’Brien SM, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies. Blood. 2017;130(Suppl. 1):4326.][Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42. DOI:10.1056/NEJMoa1215637][Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133(12):1298-307. DOI:10.1182/blood-2018-11-846808][Shafaattalab S, Lin E, Christidi E, et al. Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes. Stem Cell Reports. 2019;12(5):996-1006. DOI:10.1016/j.stemcr.2019.03.011][Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667-8.][Furman RR, Byrd JC, Owen RG, et al. Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: pooled analysis from clinical trials. J Clin Oncol. 2020;38(Suppl. 15):8064.][Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020;2020(1):336-45. DOI:10.1182/hematology.2020000118][In an interview with Targeted Oncology, Jeff P. Sharman, MD, discussed the updated ELEVATE-TN data and ongoing research that is poised to define the optimal role of acalabrutinib in CLL at the 2019 ASH Annual Meeting.][Ed. Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in treatment-naive chronic lymphocytic leukemia: mature results from phase 2 Study demonstrating durable remissions and long-term tolerability. Vol. 294983.Virtual Edition of the 25th European Hematology Association Annual Meeting. EHA Library, 2020. P. S163.]